Next Generation Cancer Diagnostics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Next Generation Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2030.
Segment by Type
Next Generation Sequencing
qPCR & Multiplexing
DNA Microarrays
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Cepheid
Koninklijke Philips N.V
F. Hoffmann-La Roche Ltd
Qiagen
Novartis AG
Abbott
Thermo Fisher Scientific
Opko Health
Myriad Genetics
Agilent Technologies
GE Healthcare
PerkinElmer
Genomic Health
Illumina
Hologic
Almac Group
Janssen Global Services
Sysmex Corporation
